Priya S, Kma L
Biochem Biophys Rep. 2025; 41:101896.
PMID: 39881957
PMC: 11774814.
DOI: 10.1016/j.bbrep.2024.101896.
Rodriguez L, Schmittdiel J, Liu L, Macdonald B, Balasubramanian S, Chai K
JAMA Netw Open. 2024; 7(7):e2421019.
PMID: 38990573
PMC: 11240192.
DOI: 10.1001/jamanetworkopen.2024.21019.
Vogl T, Adwan H, Wolff L, Lahrsow M, Gruber-Rouh T, Nour-Eldin N
Cancers (Basel). 2024; 16(8).
PMID: 38672580
PMC: 11049215.
DOI: 10.3390/cancers16081498.
Kimura M, Nishikawa K, Imamura J, Kimura K
Cureus. 2024; 16(1):e53278.
PMID: 38435911
PMC: 10905057.
DOI: 10.7759/cureus.53278.
Dharmapuri S, Ozbek U, Jethra H, Jun T, Marron T, Saeed A
World J Gastrointest Oncol. 2023; 15(11):1900-1912.
PMID: 38077640
PMC: 10701235.
DOI: 10.4251/wjgo.v15.i11.1900.
Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies.
Piratvisuth T, Hou J, Tanwandee T, Berg T, Vogel A, Trojan J
Hepatol Commun. 2023; 7(11).
PMID: 37938100
PMC: 10635602.
DOI: 10.1097/HC9.0000000000000317.
Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting.
Aly A, Fulcher N, Seal B, Pham T, Wang Y, Paulson S
Hepat Oncol. 2023; 10(1):HEP47.
PMID: 37577406
PMC: 10413176.
DOI: 10.2217/hep-2023-0002.
Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals.
Kamal A, Mohsin A, Matta C, Ghazy R, Elhadidi A, Tahoun M
Clin Exp Hepatol. 2023; 8(4):330-334.
PMID: 36683867
PMC: 9850302.
DOI: 10.5114/ceh.2022.122289.
Fibrolamellar Hepatocellular Carcinoma in the Absence of Risk Factors: A Case Report.
Bawashkhah A, Sindi G, AlMatrafi S, Obaid E, Bakhsh R
Cureus. 2022; 14(12):e32483.
PMID: 36531790
PMC: 9750232.
DOI: 10.7759/cureus.32483.
Prediction of hepatocellular carcinoma risk in patients with type-2 diabetes using supervised machine learning classification model.
Azit N, Sahran S, Leow V, Subramaniam M, Mokhtar S, Mohammed Nawi A
Heliyon. 2022; 8(10):e10772.
PMID: 36203910
PMC: 9529545.
DOI: 10.1016/j.heliyon.2022.e10772.
The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.
Zhang L, Chen C, Chai D, Li C, Guan Y, Liu L
Front Immunol. 2022; 13:956533.
PMID: 36059512
PMC: 9429218.
DOI: 10.3389/fimmu.2022.956533.
Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.
Rallis K, Makrakis D, Ziogas I, Tsoulfas G
World J Clin Oncol. 2022; 13(6):448-472.
PMID: 35949435
PMC: 9244967.
DOI: 10.5306/wjco.v13.i6.448.
Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study.
Kim H, An J, Kim J, Shin H, Park S, Song G
Liver Cancer. 2022; 11(2):141-151.
PMID: 35634426
PMC: 9109079.
DOI: 10.1159/000518837.
Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC).
Lee T, Rawding P, Bu J, Hyun S, Rou W, Jeon H
Cancers (Basel). 2022; 14(9).
PMID: 35565192
PMC: 9103537.
DOI: 10.3390/cancers14092061.
Identification of potential microRNA groups for the diagnosis of hepatocellular carcinoma (HCC) using microarray datasets and bioinformatics tools.
Dat V, Nhung B, Chau N, Cuong P, Hieu V, Linh N
Heliyon. 2022; 8(2):e08987.
PMID: 35243101
PMC: 8873536.
DOI: 10.1016/j.heliyon.2022.e08987.
Juvenile Hepatocellular Carcinoma in a Healthy Liver.
Onishi S, Tajika M, Tanaka T, Yamada K, Kamiya T, Natsume S
Intern Med. 2021; 61(10):1531-1536.
PMID: 34670900
PMC: 9177355.
DOI: 10.2169/internalmedicine.8305-21.
Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030?.
Amponsah-Dacosta E
World J Gastroenterol. 2021; 27(36):6025-6038.
PMID: 34629817
PMC: 8476331.
DOI: 10.3748/wjg.v27.i36.6025.
Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study.
Li Y, Chen A, Wang H, Han L, Wang R, Zhang G
Patient Prefer Adherence. 2021; 15:1729-1738.
PMID: 34408406
PMC: 8364380.
DOI: 10.2147/PPA.S317250.
BIR repeat-containing ubiquitin conjugating enzyme (BRUCE) regulation of β-catenin signaling in the progression of drug-induced hepatic fibrosis and carcinogenesis.
Vilfranc C, Che L, Patra K, Niu L, Olowokure O, Wang J
World J Hepatol. 2021; 13(3):343-361.
PMID: 33815677
PMC: 8006081.
DOI: 10.4254/wjh.v13.i3.343.
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.
Abd El Aziz M, Facciorusso A, Nayfeh T, Saadi S, Elnaggar M, Cotsoglou C
Vaccines (Basel). 2020; 8(4).
PMID: 33086471
PMC: 7712941.
DOI: 10.3390/vaccines8040616.
